KDEV Karolinska Development AB

arolinska Development's portfolio company OssDsign prepares for launch in Japan following regulatory filing

arolinska Development's portfolio company OssDsign prepares for launch in Japan following regulatory filing

STOCKHOLM – August 9, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign AB has filed for Japanese regulatory approval of OssDsign Cranial and initiates planning for a commercial launch in Japan, the world’s second largest market for cranioplasty implants.

OssDsign Cranial is an innovative implant for bone regeneration that is intended for cranial reconstructions. Provided an approval from the Japanese Pharmaceutical and Medical Device Agency (PDMA), OssDsign intends to launch the product during 2020 in cooperation with an appropriate local commercial partner. Selected Japanese neurosurgeons have already performed surgeries using OssDsign Cranial under ethical approval.

If granted approval, OssDsign Cranial will be the first product of its kind on the Japanese market.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit



Attachment

EN
09/08/2019

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

Year-end Report - January-December 2025

Year-end Report - January-December 2025 STOCKHOLM – 13 February 2025. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Year-end Report January-December 2025. The full report is available on the Company's website. “A stronger financial position under a new flag means we are well-positioned to continue supporting our portfolio companies in their efforts to develop new treatments in areas with substantial medical need”, says Viktor Drvota, CEO, KDventures. Significant events during the fourth quarter The portfolio company Dilafor was granted a patent in the US, protecting its drug...

3h / 16m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Bokslutskommuniké för januari – december 2025

Bokslutskommuniké för januari – december 2025 STOCKHOLM – den 13 februari 2026. KDventures AB (Nasdaq Stockholm: KDV) publicerar idag sin bokslutskommuniké för januari – december 2025. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Med en stärkt finansiell position och under ny flagg är vi väl rustade för att fortsätta stötta våra portföljbolag i arbetet att utveckla nya behandlingar inom områden med stora medicinska behov”, säger Viktor Drvota, VD, KDventures. Väsentliga händelser under fjärde kvartalet Portföljbolaget Dilafor beviljades ett patent i USA som skyddar bolagets ...

3h / 16m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures AB (publ) carries out a directed issue of shares to guarant...

KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR INVITATION TO, ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN KDVENTURES AB (PUBL) IN ANY JURISDICTION. PLEASE ALSO REFER TO...

19h / 31m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures AB (publ) genomför riktad nyemission av aktier till garante...

KDventures AB (publ) genomför riktad nyemission av aktier till garanter i samband med den genomförda företrädesemissionen EJ AVSEDD FÖR DISTRIBUTION ELLER PUBLICERING, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, KANADA, JAPAN, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDKOREA, SYDAFRIKA ELLER INOM ANNAN JURISDIKTION DÄR DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIGT. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE OM, ELLER INBJUDAN TILL, ATT FÖRVÄRVA ELLER TECKNA NÅGRA VÄRDEPAPPER I KDVENTURES AB (PUBL) I NÅGON JURISDIKTION. SE ÄVEN AVSN...

19h / 31m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as...

KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition of the company’s lead vaccine candidate SVF-001 to phase 1 clinical development. SVF Vaccines develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. Ahead of entering first-in-human phase 1 clinical development with its lead vaccine cand...

February 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch